Matthew D. Wortman

Matthew D. Wortman

Auto-generated profile, based on publicly available information

Matthew D. Wortman

Division of Endocrinology, Diabetes and Metabolism, University of Cincinnati, Cincinnati, OH, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2002 in Nature Medicine
Verified
Journal Article
Closed access
KTKellie L.K. Tamashiro
Kellie L.K. Tamashiro
TWTeruhiko Wakayama
Teruhiko Wakayama
HAHidenori Akutsu
Hidenori Akutsu
YYYukiko Yamazaki
Yukiko Yamazaki
JLJennifer L. Lachey
Jennifer L. Lachey
RSRandall R. Sakai
Randall R. Sakai

1 June 2012 in Chemistry & Biology
Verified
Journal Article
Closed access
XSXun Shang
Xun Shang
FMFillipo Marchioni
Fillipo Marchioni
NSNisha Sipes
Nisha Sipes
CEChris R. Evelyn
Chris R. Evelyn
MJMoran Jerabek-Willemsen
Moran Jerabek-Willemsen
YZYi Zheng
Yi Zheng

13 January 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
XLXiaona Liu
Xiaona Liu
RCRishi Raj Chhipa
Rishi Raj Chhipa
SPShabnam Pooya
Shabnam Pooya
MWMatthew Wortman
Matthew Wortman
SYSara Yachyshin
Sara Yachyshin
Biplab DasguptaBiplab Dasgupta
Biplab Dasgupta
Significance: Cancer cells reprogram their metabolism for optimal growth and survival. AMPK-activated protein kinase (AMPK) is a key energy sensor that controls many metabolic pathways including metabolic reprogramming. However, its role in cancer is poorly understood. Some studies claim that it has a tumor suppressor role while others show its protumor role. Two AMPK-activating compounds (including metformin, now in many clinical trials) are widely used to suppress cancer cell proliferation. We found that AMPK is abundantly expressed in high-grade gliomas and, in contrast to popular belief, these two AMPK activators suppressed glioma cell proliferation through unique AMPK-independent mechanisms.

1 April 2011 in Physiology & Behavior
Verified
Journal Article
Closed access
DCDeborah J. Clegg
Deborah J. Clegg
KGKoro Gotoh
Koro Gotoh
CKChristopher Kemp
Christopher Kemp
MWMatthew D. Wortman
Matthew D. Wortman
SBStephen C. Benoit
Stephen C. Benoit
SWStephen C. Woods
Stephen C. Woods

4 February 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
XSXun Shang
Xun Shang
FMFillipo Marchioni
Fillipo Marchioni
CEChris R. Evelyn
Chris R. Evelyn
NSNisha Sipes
Nisha Sipes
XZXuan Zhou
Xuan Zhou
YZYi Zheng
Yi Zheng
The G-protein–mediated Rho guanine nucleotide exchange factor (GEF)–Rho GTPase signaling axis has been implicated in human pathophysiology and is a potential therapeutic target. By virtual screening of chemicals that fit into a surface groove of the DH-PH domain of LARG, a G-protein–regulated Rho GEF involved in RhoA activation, and subsequent validations in biochemical assays, we have identified a class of chemical inhibitors represented by Y16 that are active in specifically inhibiting LARG binding to RhoA. Y16 binds to the junction site of the DH-PH domains of LARG with a ∼80 nM K d and suppresses LARG catalyzed RhoA activation dose dependently. It is active in blocking the interaction of LARG and related G-protein–coupled Rho GEFs with RhoA without a detectable effect on other DBL family Rho GEFs, Rho effectors, or a RhoGAP. In cells, Y16 selectively inhibits serum-induced RhoA activity and RhoA-mediated signaling, effects that can be rescued by a constitutively active RhoA or ROCK mutant. By suppressing RhoA activity, Y16 inhibits mammary sphere formation of MCF7 breast cancer cells but does not affect the nontransforming MCF10A cells. Significantly, Y16 works synergistically with Rhosin/G04, a Rho GTPase activation site inhibitor, in inhibiting LARG–RhoA interaction, RhoA activation, and RhoA-mediated signaling functions. Thus, our studies show that Rho GEFs can serve as selective targets of small chemicals and present a strategy of dual inhibition of the enzyme–substrate pair of GEF–RhoA at their binding interface that leads to enhanced efficacy and specificity.

1 June 2014 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
NHNorris I. Hollie
Norris I. Hollie
JCJames G. Cash
James G. Cash
MMM. Abdul Matlib
M. Abdul Matlib
MWMatthew Wortman
Matthew Wortman
JBJoshua E. Basford
Joshua E. Basford
DHDavid Y Hui
David Y Hui